OJ, the PR only referenced the merger between Antigen Express and Kiromics. It had nothing to do with the NGIO shares.

However, the merger provides greater opportunity for the immunotherapies to be successful. Should that occur the value of the NGIO shares would increase by increments we could hardly dare to dream about. Maybe someone else can comment more intelligently, but my guess is that the synergies acquired through the merger alone would be enough to increase Mr. Barnard's analysis of the NGIO pps.